Patients deemed to have LOW fracture risk can be discharged with the following criteria met:
Stable clinical risk factors for bone loss (not anticipated to change in the next 2-5 years)
Patients deemed to have HIGH fracture risk requiring lifelong therapy (not appropriate for drug holiday) can be discharged with the following criteria met:
Tolerating current osteoporosis therapy
Stable BMD after 1-3 years of osteoporosis therapy
No new fractures on current osteoporosis therapy
Patients currently on Bisphosphonate DRUG HOLIDAY can be discharged if the following criteria are met:
Completed bisphosphonate therapy for 3-6 years with adequate clinical response
Prior denosumab and transitioned to bisphosphonate therapy for 12 or more months, with stable BMD
No new fractures (during osteoporosis therapy)
Stable clinical risk factors for bone loss (not anticipated to change in next 2-5 years)
Patient with moderate or high risk of fracture and consistently expresses a desire not to start pharmacotherapy